Home versus Office blood pressure MEasurements: Reduction of Unnecessary treatment Study: Rationale and Study design of the HOMERUS Trial

被引:25
作者
Verberk, WJ
Kroon, AA
Kessels, AGH
Dirksen, C
Nelemans, PJ
Lenders, JWM
Thien, TABM
van Montfrans, GA
Smit, AJ
de Leeuw, PW
机构
[1] Univ Hosp Maastricht, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands
[2] Univ Hosp Maastricht, Dept Clin Epidemiol & Med Technol Assessment, NL-6202 AZ Maastricht, Netherlands
[3] Univ Hosp Maastricht, Dept Epidemiol, NL-6202 AZ Maastricht, Netherlands
[4] Maastricht Univ, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
[5] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Div Gen Internal Med, Nijmegen, Netherlands
[6] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
[7] Univ Hosp Groningen, Dept Internal Med, Groningen, Netherlands
关键词
blood pressure; cost-effectiveness; cost-minimization; home monitoring; hypertension; self-measurements; white coat effect;
D O I
10.1080/08037050310022405
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The Home versus Office MEasurements, Reduction of Unnecessary treatment Study (HOMERUS) is a multicentre prospective study, primarily designed to examine in subjects with mild to moderate hypertension whether treatment decisions based on home blood pressure measurements can lead to reduction in the use of antihypertensive drugs and the associated costs, compared to office blood pressure measurements. After inclusion, 360 patients are randomized to two groups. In one group, antihypertensive therapy is based on blood pressure measured in the outpatient clinic: the office pressure (OP) group. In the other group, antihypertensive therapy is based on home blood pressure measurements: the self-pressure (SP) group. All readings, both in OP and in SP, are obtained with the same validated oscillometric device, the Omron 705 CP. Treatment decisions are taken by an independent physician at the coordinating centre, who is unaware whether the patient belongs to the SP or OP group. Following a standardized treatment schedule, blood pressure is targeted at 120-139 mmHg for systolic and 80-89 mmHg for diastolic pressure. Patients are followed for 1 year. At the start and at the end of the study, ambulatory blood pressure measurements are obtained as a reference. Microalbuminuria and echocardiography are assessed to evaluate the possible development of target organ damage. It is expected that, at the end of the trial, patients in both groups will have the same blood pressure, at the expense of more medication in the OP group. Therefore, a cost-minimization analysis will be performed first. If short-term effects appear not to be comparable for OP and SP, a cost-effectiveness analysis will be performed to assess the value of the SP strategy in comparison to standard practice. In addition, medication compliance is recorded within random subgroups of the SP and OP groups by means of Medication Event Monitoring System (MEMS) V TrackCaps.
引用
收藏
页码:326 / 333
页数:8
相关论文
共 36 条
[1]  
Arabidze, 1996, Blood Press Monit, V1, P321
[2]   Relationship between home blood pressure measurement and medication compliance and name recognition of antihypertensive drugs [J].
Ashida, T ;
Sugiyama, T ;
Okuno, S ;
Ebihara, A ;
Fujii, J .
HYPERTENSION RESEARCH, 2000, 23 (01) :21-24
[3]  
Aylett M, 1999, BRIT J GEN PRACT, V49, P725
[4]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[5]   THE MEASUREMENT OF QUALITY OF LIFE IN HYPERTENSIVE PATIENTS - A PRACTICAL APPROACH [J].
BULPITT, CJ ;
FLETCHER, AE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (03) :353-364
[6]   Home self blood pressure measurement in general practice - The SMART study [J].
Chatellier, G ;
DutreyDupagne, C ;
Vaur, L ;
Zannad, F ;
Genes, N ;
Elkik, F ;
Menard, J .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (07) :644-652
[7]   HOME BLOOD-PRESSURE RECORDING [J].
CONWAY, J .
CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1986, 8 (08) :1247-1294
[8]  
Denolle T, 2000, BLOOD PRESS MONIT, V5, P145
[9]  
*ESH ESC HYP GUID, 2003, J HYPERTENS, V21, P1779
[10]  
Fagard, 1996, Blood Press Monit, V1, P279